These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 29561206)

  • 1. Venous thromboembolism in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with lenalidomide: a systematic review.
    Sorigue M; Orna E; Sancho JM
    Leuk Lymphoma; 2018 Nov; 59(11):2602-2611. PubMed ID: 29561206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis.
    Yamshon S; Christos PJ; Demetres M; Hammad H; Leonard JP; Ruan J
    Blood Adv; 2018 Jun; 2(12):1429-1438. PubMed ID: 29934343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis.
    Chakraborty R; Bin Riaz I; Malik SU; Marneni N; Mejia Garcia A; Anwer F; Khorana AA; Rajkumar SV; Kumar S; Murad MH; Wang Z; Khan SU; Majhail NS
    Cancer; 2020 Apr; 126(8):1640-1650. PubMed ID: 31913498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
    Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
    Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Application of lenalidomide in chronic lymphocytic leukemia].
    Lei W; Zhou KS; Li YF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):565-8. PubMed ID: 24763044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611).
    Tallarico M; Foster JC; Seisler D; Lafky JM; Hurria A; Jatoi A; Cohen HJ; Muss HB; Bartlett N; Cheson BD; Jung SH; Leonard JP; Byrd JC; Nabhan C
    J Geriatr Oncol; 2018 Jul; 9(4):321-328. PubMed ID: 29673807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide in lymphomas and chronic lymphocytic leukemia.
    Wiernik PH
    Expert Opin Pharmacother; 2013 Mar; 14(4):475-88. PubMed ID: 23356486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia.
    Thangavadivel S; Zhao Q; Epperla N; Rike L; Mo X; Badawi M; Bystry DM; Phelps MA; Andritsos LA; Rogers KA; Jones J; Woyach JA; Byrd JC; Awan FT
    Clin Cancer Res; 2020 Dec; 26(23):6187-6195. PubMed ID: 32958702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain.
    Sanchez-Gonzalez B; Peñalver FJ; Medina A; Guillén H; Calleja M; Gironella M; Arranz R; Sebastian E; de Oña R; Cánovas A; de la Fuente I; Grande C; Sancho JM; Perez R; Domingo E; Lopez-Lorenzo JL; Prieto E; Panizo C; Gorosquieta A; Perez I; Cervera JM; Marin M; Mencha C; Ramila E; Salar A
    Leuk Res; 2012 Jun; 36(6):709-14. PubMed ID: 22154023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanoma in patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma.
    Famenini S; Martires KJ; Zhou H; Xavier MF; Wu JJ
    J Am Acad Dermatol; 2015 Jan; 72(1):78-84. PubMed ID: 25440434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of venous thromboembolism in patients with non-Hodgkin lymphoma.
    Sanfilippo KM; Wang TF; Gage BF; Luo S; Riedell P; Carson KR
    Thromb Res; 2016 Jul; 143():86-90. PubMed ID: 27208462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin.
    Czuczman MS; Vose JM; Witzig TE; Zinzani PL; Buckstein R; Polikoff J; Li J; Pietronigro D; Ervin-Haynes A; Reeder CB
    Br J Haematol; 2011 Aug; 154(4):477-81. PubMed ID: 21707581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venous thromboembolism incidence in hematologic malignancies.
    Kekre N; Connors JM
    Blood Rev; 2019 Jan; 33():24-32. PubMed ID: 30262170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PO-03 - Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL).
    Santi RM; Ceccarelli M; Catania G; Monagheddu C; Evangelista A; Bernocco E; Monaco F; Federico M; Vitolo U; Cortelazzo S; Cabras MG; Spina M; Baldini L; Boccomini C; Chiappella A; Bari A; Luminari S; Calabrese M; Levis A; Visco C; Contino L; Ciccone G; Ladetto M
    Thromb Res; 2016 Apr; 140 Suppl 1():S177. PubMed ID: 27161692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venous thromboembolism in patients with chronic lymphocytic leukemia.
    Šimkovič M; Vodárek P; Motyčková M; Belada D; Vrbacký F; Žák P; Smolej L
    Thromb Res; 2015 Dec; 136(6):1082-6. PubMed ID: 26467608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone.
    Shin J; Lee JJ; Kim K; Min CK; Lee JO; Suh C; Kim JS; Lee YJ; Yoon SS; Jo JC; Lee HS; Bang SM;
    Int J Hematol; 2019 Jan; 109(1):79-90. PubMed ID: 30291558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide.
    Fürstenau M; Fink AM; Schilhabel A; Weiss J; Robrecht S; Eckert R; de la Serna J; Crespo M; Coscia M; Vitale C; Böttcher S; Weppner G; Ritgen M; Stilgenbauer S; Tausch E; Fischer K; Hallek M; Eichhorst B; Brüggemann M; Herling CD
    Blood; 2021 Apr; 137(16):2267-2271. PubMed ID: 33512465
    [No Abstract]   [Full Text] [Related]  

  • 18. Venous thromboembolism in chronic lymphocytic leukemia: a Danish nationwide cohort study.
    Gade IL; Riddersholm SJ; Christiansen I; Rewes A; Frederiksen M; Enggaard L; Poulsen CB; Bergmann OJ; Gillström DB; Pedersen RS; Nielsen L; Eriksen HH; Torp-Pedersen C; Kristensen SR; Severinsen MT
    Blood Adv; 2018 Nov; 2(21):3025-3034. PubMed ID: 30425066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis.
    Liang L; Zhao M; Zhu YC; Hu X; Yang LP; Liu H
    Ann Hematol; 2016 Sep; 95(9):1473-82. PubMed ID: 27329288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prednimustine and mitoxantrone (PmM) in patients with low-grade malignant non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and prolymphocytic leukemia (PLL).
    Freund M; Wunsch-Zeddies S; Schäfers M; Wysk J; Seidel I; Hiddemann W; Hanauske AR; Link H; Schmoll HJ; Poliwoda H
    Ann Hematol; 1992 Feb; 64(2):83-7. PubMed ID: 1554799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.